Product/Composition:- | Voriconazole Tablets |
---|---|
Strength:- | 50 mg, 200 mg |
Form:- | Tablets |
Reference Brands:- | Vfend(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Voriconazole tablets inhibit fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and fungal cell membrane formation. They provide broad-spectrum antifungal activity, including against Aspergillus and Candida. Benefits include oral administration, excellent tissue penetration, rapid action, and high efficacy in treating invasive fungal infections, improving patient outcomes.
Voriconazole tablets are approved in the EU and US for treating invasive fungal infections. In the EU, Pfizer’s Vfend is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality. In the US, FDA approval is based on comprehensive clinical data, biosimilarity, and pharmacovigilance. Both regions require detailed dossiers for initial authorization and ongoing safety monitoring. For expert assistance with pharmaceutical dossiers, regulatory submissions, and compliance, visit PharmaTradz, your trusted partner in regulatory solutions. We help ensure smooth market access and adherence to European and American standards for voriconazole tablets, supporting your product’s global success.